Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists (GLP-1 RAs), originally for type 2 diabetes and obesity, showed promise in slowing kidney disease progression and lowering cardiovascular risks in lupus patients. Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists (GLP-1 RAs), originally for type 2 diabetes and obesity, showed promise in slowing kidney disease progression and lowering cardiovascular risks in lupus patients. Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle
